Intracranial Outcomes of 1L Selpercatinib in Advanced RET fusion-positive (RET plus ) NSCLC: LIBRETTO-431 study

被引：0

作者：

Perol, Maurice ^{[1
]}

Solomon, Ben J. ^{[2
]}

Goto, Koichi ^{[3
]}

Park, Keunchil ^{[4
]}

Nadal, Ernest ^{[5
]}

Bria, Emilio ^{[6
]}

Martin, Claudio ^{[7
]}

Bar, Jair ^{[8
]}

Williams, Justin ^{[9
]}

Puri, Tarun ^{[9
]}

Li, Jian ^{[10
]}

Uh, Minji ^{[9
]}

Lin, Boris ^{[9
]}

Zhou, Caicun ^{[11
]}

Pruthi, Aarohan ^{[9
]}

机构：

[1] Ctr Leon Berard, Lyon, France

[2] Peter MacCallum Canc Inst, Melbourne, Vic, Australia

[3] Natl Canc Ctr Hosp East, Chiba, Japan

[4] Samsung Med Ctr, Seoul, South Korea

[5] Inst Catala Oncol, Barcelona, Spain

[6] Fdn Policlin Univ Agostino Gemelli IRCCS, Rome, Italy

[7] Inst Alexander Fleming, Buenos Aires, DF, Argentina

[8] Sheba Med Ctr, Inst Oncol, Ramat Gan, Israel

[9] Eli Lilly, Indianapolis, IN USA

[10] Loxo Lilly, Indianapolis, IN USA

[11] Shanghai Pulm Hosp, Shanghai, Peoples R China

来源：

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 20卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

259

引用

页码：138 / 138

页数：1

共 50 条

[21] Patient-reported outcomes of first-line selpercatinib versus chemotherapy with or without pembrolizumab in RET fusion-positive advanced non-small cell lung cancer: Interim analysis of LIBRETTO-431
Goto, K.
Novello, S.
Garrido Lopez, P.
Dooms, C.
Alatorre Alexander, J. A.
Reinmuth, N.
Gilligan, A.
Payakachat, N.
Lin, A.
Cocks, K.
Worthy, G.
Zhou, C.
ANNALS OF ONCOLOGY, 2023, 34 : S1654 - S1655
[22] Central Nervous System Disease in Patients With RET Fusion-Positive NSCLC Treated With Selpercatinib
Murciano-Goroff, Yonina R.
Falcon, Christina J.
Lin, Sabrina T.
Chacko, Christina
Grimaldi, Grace
Liu, Dazhi
Wilhelm, Clare
Iasonos, Alexia
Drilon, Alexander
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (05) : 620 - 627
[23] LURET study: A phase II study of vandetanib, RET inhibitor in patients with advanced RET fusion-positive NSCLC
Yoh, Kiyotaka
Seto, Takashi
Satouchi, Miyako
Nishio, Makoto
Yamamoto, Noboru
Murakami, Haruyasu
Nogami, Naoyuki
Yamanaka, Takeharu
Goto, Koichi
ANNALS OF ONCOLOGY, 2015, 26 : 91 - 91
[24] Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 Trial
Subbiah, Vivek
Gainor, Justin F.
Oxnard, Geoffrey R.
Tan, Daniel S. W.
Owen, Dwight H.
Cho, Byoung Chul
Loong, Herbert H.
Mccoach, Caroline E.
Weiss, Jared
Kim, Yu Jung
Bazhenova, Lyudmila
Park, Keunchil
Daga, Haruko
Besse, Benjamin
Gautschi, Oliver
Rolfo, Christian
Zhu, Edward Y.
Kherani, Jennifer F.
Huang, Xin
Kang, Suhyun
Drilon, Alexander
CLINICAL CANCER RESEARCH, 2021, 27 (15) : 4160 - 4167
[25] FDA Approval Summary: Selpercatinib for the Treatment of Advanced RET Fusion-Positive Solid Tumors
Duke, Elizabeth S.
Bradford, Diana
Marcovitz, Michelle
Amatya, Anup K.
Mishra-Kalyani, Pallavi S.
Nguyen, Emily
Price, Lauren S. L.
Zirkelbach, Jeanne Fourie
Li, Yangbing
Bi, Youwei
Kraft, Jeffrey
Dorff, Sarah E.
Scepura, Barbara
Stephenson, Maritsa
Ojofeitimi, Idara
Nair, Abhilasha
Han, Yu
Tezak, Zivana
Lemery, Steven J.
Pazdur, Richard
Larkins, Erin
Singh, Harpreet
CLINICAL CANCER RESEARCH, 2023, 29 (18) : 3573 - 3578
[26] In Reply to "Selpercatinib Controls Central Nervous System Disease in Patients With RET Fusion-Positive NSCLC"
Murciano-Goroff, Yonina R.
Lin, Sabrina T.
Wilhelm, Clare
Iasonos, Alexia
Drilon, Alexander
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (05) : E52 - E53
[27] Real-World Outcomes of Pralsetinib in RET Fusion-Positive NSCLC
Lucibello, Francesca
Gounant, Valerie
Aldea, Mihaela
Duruisseaux, Michael
Perol, Maurice
Chouaid, Christos
Bennouna, Jaafar
Fallet, Vincent
Renault, Aldo
Guisier, Florian
Giroux-Leprieur, Etienne
Wislez, Marie
Toffart, Anne-Claire
Mazieres, Julien
Basse, Clemence
Hegarat, Nadia
Carton, Matthieu
Girard, Nicolas
JTO CLINICAL AND RESEARCH REPORTS, 2025, 6 (01):
[28] LIBRETTO-432: A Placebo-Controlled Phase 3 Study of Adjuvant Selpercatinib in Stage IB-IIIA RET Fusion-Positive NSCLC
Goldman, J.
Besse, B.
Wu, Y.
Yang, J. C.
Paz-Ares, L.
Drilon, A.
Johnson, M.
Xia, M.
Chao, B. H.
Tsuboi, M.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S975 - S976
[29] Updated tumor agnostic efficacy of selpercatinib in patients with RET fusion-positive solid tumors: LIBRETTO-001
Ohe, Y.
Subbiah, V.
Sukrithan, V.
Robinson, B.
Deschler-Baier, B.
Iwasa, T.
Ohashi, K.
Goto, K.
Nishio, M.
Satouchi, M.
Nakamura, K.
Ashiguchi, S.
Lin, Y.
Szymczak, S.
Drilon, A.
ANNALS OF ONCOLOGY, 2024, 35 : S1322 - S1322
[30] Selective RET inhibitors shift the treatment pattern of RET fusion-positive NSCLC and improve survival outcomes
Chang Lu
Xue-Wu Wei
Yi-Chen Zhang
Zhi-Hong Chen
Chong-Rui Xu
Ming-Ying Zheng
Jin-Ji Yang
Xu-Chao Zhang
Qing Zhou
Journal of Cancer Research and Clinical Oncology, 2023, 149 : 2987 - 2995

← 1 2 3 4 5 →